Our Innovation Platform, Hutchison MediPharma, has developed and progressed our broad pipeline of novel oral drug candidates for cancer and inflammation is in development in North America, Europe, Greater China and Australia. We have taken a chemistry-focused approach to develop highly selective small molecule tyrosine kinase inhibitors that are intended to have potentially global best-in-class efficacy and are deliberately engineered to improve drug exposure and reduce known class-related toxicities.
We have also developed a profitable Commercial Platform, which manufactures, markets and distributes prescription drugs and consumer health products in China.
Chi-Med is listed on the London Stock Exchange’s AIM market and on the Nasdaq Global Select Market (AIM/Nasdaq: HCM). It is majority owned by CK Hutchison Holdings Limited (SEHK: 0001), a leading international conglomerate committed to innovation and technology with over a quarter of a million employees in more than 50 countries and annual sales of over US$50 billion.